5-amino-3-phenylisothiazole-4-carboxamide | 158042-65-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-amino-3-phenylisothiazole-4-carboxamide
• 英文别名: 5-Amino-3-phenyl-1,2-thiazole-4-carboxamide；5-amino-3-phenyl-1,2-thiazole-4-carboxamide
• CAS: 158042-65-0
• 化学式: C₁₀H₉N₃OS
• 分子量: 219.267
• InChiKey: WKGLNELSPKSJGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-amino-3-phenylisothiazole-4-carboxamide 在 劳森试剂 、 乙酸酐 作用下， 以 甲苯 为溶剂， 反应 5.0h， 生成 3-phenylisothiazolo<5,4-d>pyrimidine-4(5H)-thione
  参考文献：
  名称：

  Kappe, C. Oliver; Flammang, Robert; Wentrup, Curt, Heterocycles, 1994, vol. 37, # 3, p. 1615 - 1622

  摘要：

  DOI：
• 作为产物：
  描述：

  alpha-氯苄亚基丙二腈 在 ammonium hydroxide 、 硫酸 、 硫化氢 、 双氧水 、 三乙胺 作用下， 以 甲醇 、 苯 为溶剂， 反应 7.5h， 生成 5-amino-3-phenylisothiazole-4-carboxamide
  参考文献：
  名称：

  Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation

  摘要：

  The synthesis and structure-activity relationship studies of isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors are discussed. The pharmacokinetic profile of 10 and 21 with adequate CNS penetration, required for in vivo Parkinson's disease models, are disclosed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.025

文献信息

• 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS
  申请人：Allergan, Inc.

  公开号：US20130172353A1

  公开（公告）日：2013-07-04

  This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 , R 3 , n, X 1 , X 2 , L 1 , and L 2 are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

  本发明涉及公式I的化合物或其药学上可接受的盐，其中R、R1、R2、R3、n、X1、X2、L1和L2的定义如本文所述。公式I的化合物可用作受体酪氨酸激酶（RTK）抑制剂，并可用于治疗癌症、血管增殖性疾病、纤维性疾病、系膜细胞增殖性疾病和代谢性疾病。
• 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CABOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS
  申请人：ALLERGAN, INC.

  公开号：EP3184525A1

  公开（公告）日：2017-06-28

  This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, n, X1, X2, L1, and L2 are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

  本发明涉及一种式 I 的化合物 或其药学上可接受的盐，其中 R、R1、R2、R3、n、X1、X2、L1 和 L2 如本文所定义。式 I 的化合物是有用的受体酪氨酸激酶（RTK）抑制剂，可用于治疗癌症、血管增生性疾病、纤维化疾病、间质细胞增生性疾病和代谢性疾病等疾病。
• US8969583B2
  申请人：——

  公开号：US8969583B2

  公开（公告）日：2015-03-03
• Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation
  作者：Abhisek Banerjee、Pravin S. Yadav、Malini Bajpai、Ramachandra Rao Sangana、Srinivas Gullapalli、Girish S. Gudi、Laxmikant A. Gharat

  DOI：10.1016/j.bmcl.2012.03.025

  日期：2012.5

  The synthesis and structure-activity relationship studies of isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors are discussed. The pharmacokinetic profile of 10 and 21 with adequate CNS penetration, required for in vivo Parkinson's disease models, are disclosed. (C) 2012 Elsevier Ltd. All rights reserved.
• Kappe, C. Oliver; Flammang, Robert; Wentrup, Curt, Heterocycles, 1994, vol. 37, # 3, p. 1615 - 1622
  作者：Kappe, C. Oliver、Flammang, Robert、Wentrup, Curt

  DOI：——

  日期：——